439

E. Hawkey and J. T. Nigg, “Omega3 Fatty Acid and ADHD: Blood Level Analysis and Meta-Analytic Extension of Supplementation Trials,” Clinical Psychology Review 34, no. 6 (August 2014): 496–505, doi: 10.1016/j.cpr.2014.05.005; C. M. Milte et al., “Increased Erythrocyte Eicosapentaenoic Acid and Docosahexaenoic Acid Are Associated with Improved Attention and Behavior in Children with ADHD in a Randomized Controlled Three-Way Crossover Trial,” Journal of Attention Disorders 19, no. 11 (November 2015): 954–64, doi: 10.1177/1087054713510562; K. Widenhorn-Muller et al., “Effect of Supplementation with Long-Chain Ω3 Polyunsaturated Fatty Acids on Behavior and Cognition in Children with Attention Deficit/Hyperactivity Disorder (ADHD): A Randomized Placebo-Controlled Intervention Trial,” Prostaglandins, Leukotrienes, and Essential Fatty Acids 91, nos. 1–2 (July – August 2014): 49–60, doi: 10.1016/j.plefa.2014.04.004; H. Perera et al., “Combined Ω3 and Ω6 Supplementation in Children with Attention-Deficit Hyperactivity Disorder (ADHD) Refractory to Methylphenidate Treatment: A Double-Blind, Placebo-Controlled Study,” Journal of Child Neurology 27, no. 6 (June 2012): 747–53, doi: 10.1177/0883073811435243; D. J. Bos et al., “Reduced Symptoms of Inattention after Dietary Omega3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder,” Neuropsychopharmacology 40, no. 10 (September 2015): 2298–306, doi: 10.1038/npp.2015.73.